C014CIP/DIV2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
Group : Not Yet Assigned
Applicants : Michael J. Yellin et al.
Serial No. : Not Yet Assigned
Filed : Concurrently herewith
For : THERAPEUTIC APPLICATIONS FOR THE ANTI-T-
BAM (CD40-L) MONOCLONAL ANTIBODY 5C8



New York, New York
June 29, 1999

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b)

applicants make of record the following documents*:

1. United States patent: 5,474,771
Patentee: Lederman et al.
Issue date: December 12, 1995
2. United States patent: 5,540,926
Patentee: Aruffo et al.
Issue date: June 30, 1996.
3. United States patent: 5,674,492
Patentee: Armitage et al.
Issue date: October 7, 1997.
4. United States patent: 5,677,165
Patentee: de Boer et al.
Issue date: October 14, 1997.

* For the Examiner's convenience, applicants have enclosed a completed Form PTO-1449, listing these documents.

5. United States patent: 5,683,693
Patentee: Noelle et al.
Issue date: November 4, 1997.
6. United States patent: 5,747,037
Patentee: Noelle et al.
Issue date: May 5, 1998.
7. United States patent: 5,833,987
Patentee: Noelle et al.
Issue date: November 10, 1998
8. PCT patent application: WO 93/08207
Publication date: April 29, 1993.
9. PCT patent application: WO 93/09812
Publication date: May 27, 1993.
10. PCT patent application: WO 94/04570
Publication date: March 3, 1994.
11. PCT patent application: WO 95/06481
Publication date: March 9, 1995.
12. PCT patent application: WO 95/06666
Publication date: March 9, 1995.
13. PCT patent application: WO 95/09653
Publication date: April 13, 1995.
14. PCT patent application: WO 96/23071
Publication date: August 1, 1996.
15. PCT patent application: WO 96/28568
Publication date: September 19, 1996.
16. PCT patent application: WO 96/40246
Publication date: December 19, 1996.
17. PCT patent application: WO 97/17446
Publication date: May 15, 1997.

Articles

Alderson, M.R. et al. "CD40 Expression By Human Monocytes: Regulation By Cytokines And Activation Of Monocytes By The Ligand For CD40", *J. Exp. Med.* 178:669-674 (1993).

Bajorath J. et al. "Identification of Residues on CD40 and Its Ligand Which Are Critical for the Receptor-Ligand Interaction", *Biochemistry* 34:1833-1844 (1995).

Banchereau J. et al. "The CD40 Antigen and its Ligand", *Annual Rev. Immunol.* 12:881-922 (1994).

Biancone, L. et al. "Inhibition of the CD40-CD40Ligand Pathway Prevents Murine Membranous Glomerulonephritis", *Kidney Intl.* 48:458-468 (1995).

Buhlmann, J.E. et al. "Therapeutic Potential For Blockade of the CD40 Ligand, gp39", *J. Clin. Immunol.* 16:83-89 (1996).

Carbone, A. et al. "Expression of Functional CD40 Antigen on Reed-Sternberg Cells and Hodgkin's Disease Cell Lines", *Blood* 85(3):780-789 (1995).

Clark, E.A. et al. "Activation of Human B Cells Mediated Through Two Distinct Cell Surface Differentiation Antigens, Bp35 and Bp50", *Proc. Natl. Acad. Sci., USA* 83:4494-4498 (1986).

Cleary, A. M. et al. "Opposing Roles of CD95 (Fas/APO-1) and CD40 in the Death and Rescue of Human Low Density Tonsillar B Cells", *J. Immunol.* 155:3329-3337 (1995).

Durie, F.H. et al. "The Role of CD40 and its Ligand (gp39) in Peripheral and Central Tolerance and its Contribution to Autoimmune Disease", *Res. Immunol.* 145:200-205 (1994).

Durie, F.H. et al. "The Role of CD40 in the Regulation of Humoral and Cell-Mediated Immunity", *Immunol. Today* 15:406-411 (1994).

Durie, F.H. et al. "Prevention of Collagen-Induced Arthritis With An Antibody to gp39, the Ligand for CD40", *Science* 261:1328-1330 (1993).

Fanslow W. C. et al. "Soluble Forms of CD40 Inhibit Biologic Responses of Human B Cells", *J. Immunol.* 149:655-660 (1992).

Freudenthal, P.S. et al. "The Distinct Surface of Human Blood Dendritic Cells, As Observed After An Improved Isolation Method", *Proc. Natl. Acad. Sci., USA* 87:7698-7702 (1990).

Galy, A.H.M. et al. "CD40 is Functionally Expressed on Human Thymic Epithelial Cells", *J. Immunol.* 149:775-782 (1992).

Gray, D. et al "Memory B Cell Development But Not Germinal Center Formation is Impaired by In Vivo Blockade of CD-40-CD40 Ligand Interaction", *J. Exp. Med.* 180:141-154 (1994).

Hasbold, J. et al. "Properties of Mouse CD40: Cellular Distribution of CD40 and B Cell Activation by Monoclonal Anti-Mouse CD40 Antibodies", *Eur. J. Of Immunol.* 24:1835-1842 (1994).

Hollenbaugh, D. et al. "Expression of Functional CD40 by Vascular Endothelial Cells", *J. Exp. Med.* 182:33-40 (1995).

Karmann, K. et al. "CD40 on Human Endothelial Cells: Inducibility by Cytokines and Functional Regulation of Adhesion Molecule Expression", *Proc. Natl. Acad. Sci., USA* 92:4342-4346 (1995).

Karpusas, M. et al. "2Å Crystal Structure of an Extracellular Fragment of Human CD40 Ligand", *Structure* 3(10): 1031-1039 (1995).

Kuntz, I.D. "Structure-Based Strategies for Drug Design and Discovery", *Science* 257:1078-1082 (1992).

Kuwana, M. et al. "T and B Cell Collaboration is Essential for the Autoantibody Response to DNA Topoisomerase 1 in Systemic Sclerosis", *J. Immunol.* 155:2703-2714 (1995).

Laman, J.D. et al. "The Role of GP39 (CD40 Ligand) in EAE and MS", *J. Neuroimmunology* 54:175 (1994).

Larsen, C.P. et al. "CD40-gp39 Interactions Play A Critical Role During Allograft Rejection", *Transplantation* 61:4-9 (1996).

Law, C-L. et al. "Analysis of Expression and Function of CD40 on Normal and Leukemic Human B Cell Precursors", *Leukemia* 4(11):732-738 (1990).

Lederman, S. et al. "The Understanding of Contact-Dependent T-Cell Helper Function in Molecular, Cellular and Physiological Detail", *Res. Immunol.* 145:215-222 (1994).

Mohan, C. et al. "Interaction Between CD40 and Its Ligand gp39 in the Development of Murine Lupus Nephritis", *J. Immunol.* 154:1470-1480 (1995).

Merck Manual of Diagnosis And Therapy, 16th Ed. "Idiopathic Infiltrative Diseases Of The Lungs", Merck Research Laboratories, Rahway, NJ 718-720 (1992).

O'Grady, J.T. et al. "CD40 Expression in Hodgkin's Disease", *Am. J. Of Pathology* 144:(1):2126 (1994).

Paulie, S. et al. "A p50 Surface Antigen Restricted to Human Urinary Bladder Carcinomas and B Lymphocytes", *Cancer Immunol. Immunother.* 20:23-28 (1985).

Potocnik, A.J. et al. "Expression of Activation Antigens on T Cells in Rheumatoid Arthritis Patients", *Scand. J. Immunol.* 31:213-224 (1990).

Stüber, E. et al. "Blocking The CD-40L-CD-40 Interaction In Vivo Specifically Prevents the Priming of T Helper 1 Cells

Through the Inhibition of Interleukin 12 Secretion", *J. Exp. Med.* 183: 693-698 (1996).

Uckun, F.M. et al. "Temporal Association of CD40 Antigen Expression With Discrete Stages of Human B-Cell Ontogeny and the Efficacy Of Anti-CD40 Immunotoxins Against Clonogenic B-Lineage Acute Lymphoblastic Leukemia As Well As B-Lineage Non-Hodgkin's Lymphoma Cells", *Blood* 76(12):2449-2456 (1990).

Urashima, M. et al. "CD40 Ligand Triggered Interleukin-6 Secretion In Multiple Myeloma", *Blood* 85:1903-1912 (1995).

Valent, P. et al. "Further Characterization Of Surface Membrane Structures Expressed On Human Basophils And Mast Cells", *Int. Arch. Allergy Appl. Immunol.* 91:198-203 (1990).

Westendorf, J.J. et al. "Molecular And Biological Role Of CD40 In Multiple Myeloma", *Curr. Top. Microbiol. Immunol.* 194:63-72 (1995).

Westendorf, J.J. et al. "CD40 Expressions In Malignant Plasma Cells", *J. Of Immunol.* 152:117-128 (1994).

Yellin, M.J. et al. "FASEB J. (March 10, 1995) 9(4):A774, Abstract No. 4483 - Oral presentation at FASEB Meeting in Atlanta, Georgia" (1995).

Yellin, M.J. et al. "Human Fibroblasts and Endothelial Cells Express CD40 and are Activated by CD40L+ Cells," Poster session at 9th International Congress of Immunology meeting in San Francisco, California (Abstract available July 23, 1995).

Yellin, M.J. et al. "Ligation Of CD40 On Fibroblasts Induces CD54 (ICAM-1) and CD106 (VCAM-1) Upregulation And IL-6 Production And Proliferation," *J. Leukocyte Biology* 58:209-216 (1995).

Yellin, M.J. et al. "Functional Interactions Of T Cells With Endothelial Cells: The Role Of CD40L-CD40-Mediated Signals," *J. Exp. Med.* 182:1857-1864 (1995).

Yellin M. J. et al. "In situ Characterization of CD40L and CD40 Expression in Glomerulonephritis (GN)", Abstract May 1, 1996: ASBMB/ASIP/AAL Joint Meeting.


Yellin M. J. et al. "Function of CD40 Molecules Expressed on Cultured Synovial Membrane Fibroblasts", *FASEB J.* 9:A774 - Abstract No. 4483 (1995).

Young, L.S. et al. "Identification Of A Human Epithelial Cell Surface Protein Sharing An Epitope With The C3d/Epstein-Barr Virus Receptor Molecule Of B Lymphocytes," *Int. J. Cancer* 43:786-794 (1989).

The listed documents were cited by applicants or the Examiner in parent application Serial No. 08/637,323, filed April 26, 1996, from which the present application claims priority under 35 U.S.C. § 120. Accordingly, pursuant to 37 C.F.R. § 1.98(d), copies of the cited documents are not enclosed.

Applicants respectfully request that the above-cited documents be (1) fully considered by the Examiner during examination of this application and (2) printed on any patent issuing from this application. In addition, applicants request that a copy of the enclosed Form PTO-1449, duly initialed by the Examiner, be forwarded to the undersigned with the next communication in this application.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)
Margaret A. Pierri (Reg. No. 30,709)
Attorneys for Applicants
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020
Tel.: (212) 596-9000
Fax.: (212) 596-9090

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
CO14CIP DIV2

SERIAL NO.
Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT
Michael J. Yellin et al.

FILING DATE
Concurrently Herewith

GROUP
Not Yet Assigned

U.S. PATENT DOCUMENTS

[illegible]

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CO14CIP DIV2	SERIAL NO. Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Michael J. Yellin et al.	
		FILING DATE Concurrently Herewith	GROUP Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Alderson, M.R. et al. "CD40 Expression By Human Monocytes: Regulation By Cytokines And Activation Of Monocytes By The Ligand For CD40", <i>J. Exp. Med.</i> 178:669-674 (1993).
	Bajorath J. et al. "Identification of Residues on CD40 and Its Ligand Which Are Critical for the Receptor-Ligand Interaction", <i>Biochemistry</i> 34:1833-1844 (1995).
	Banchereau J. et al. "The CD40 Antigen and its Ligand", <i>Annual Rev. Immunol.</i> 12:881-922 (1994).
	Biancone, L. et al. "Inhibition of the CD40-CD40Ligand Pathway Prevents Murine Membranous Glomerulonephritis", <i>Kidney Intl.</i> 48:458-468 (1995).
	Buhlmann, J.E. et al. "Therapeutic Potential For Blockade of the CD40 Ligand, gp39", <i>J. Clin. Immunol.</i> 16:83-89 (1996).
	Carbone, A. et al. "Expression of Functional CD40 Antigen on Reed-Sternberg Cells and Hodgkin's Disease Cell Lines", <i>Blood</i> 85(3):780-789 (1995).
	Clark, E.A. et al. "Activation of Human B Cells Mediated Through Two Distinct Cell Surface Differentiation Antigens, Bp35 and Bp50", <i>Proc. Natl. Acad. Sci., USA</i> 83:4494-4498 (1986).
	Cleary, A. M. et al. "Opposing Roles of CD95 (Fas/APO-1) and CD40 in the Death and Rescue of Human Low Density Tonsillar B Cells", <i>J. Immunol.</i> 155:3329-3337 (1995).
	Durie, F.H. et al. "The Role of CD40 and its Ligand (gp39) in Peripheral and Central Tolerance and its Contribution to Autoimmune Disease", <i>Res. Immunol.</i> 145:200-205 (1994).
	Durie, F.H. et al. "The Role of CD40 in the Regulation of Humoral and Cell-Mediated Immunity", <i>Immunol. Today</i> 15:406-411 (1994).
	Durie, F.H. et al. "Prevention of Collagen-Induced Arthritis With An Antibody to gp39, the Ligand for CD40", <i>Science</i> 261:1328-1330 (1993).
	Fanslow W. C. et al. "Soluble Forms of CD40 Inhibit Biologic Responses of Human B Cells", <i>J. Immunol.</i> 149:655-660 (1992).
	Freudenthal, P.S. et al. "The Distinct Surface of Human Blood Dendritic Cells, As Observed After An Improved Isolation Method", <i>Proc. Natl. Acad. Sci., USA</i> 87:7698-7702 (1990).
	Galy, A.H.M. et al. "CD40 is Functionally Expressed on Human Thymic Epithelial Cells", <i>J. Immunol.</i> 149:775-782 (1992).
	Gray, D. et al "Memory B Cell Development But Not Germinal Center Formation is Impaired by In Vivo Blockade of CD-40-CD40 Ligand Interaction", <i>J. Exp. Med.</i> 180:141-154 (1994).
	Hasbold, J. et al. "Properties of Mouse CD40: Cellular Distribution of CD40 and B Cell Activation by Monoclonal Anti-Mouse CD40 Antibodies", <i>Eur. J. Of Immunol.</i> 24:1835-1842 (1994).
	Hollenbaugh, D. et al. "Expression of Functional CD40 by Vascular Endothelial Cells", <i>J. Exp. Med.</i> 182:33-40 (1995).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CO14CIP DIV2SERIAL NO.
Not Yet AssignedINFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Michael J. Yellin et al.FILING DATE
Concurrently HerewithGROUP
Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Karmann, K. et al. "CD40 on Human Endothelial Cells: Inducibility by Cytokines and Functional Regulation of Adhesion Molecule Expression", <i>Proc. Natl. Acad. Sci., USA</i> 92:4342-4346 (1995).
	Karpusas, M. et al. "2Å Crystal Structure of an Extracellular Fragment of Human CD40 Ligand", <i>Structure</i> 3(10): 1031-1039 (1995).
	Kuntz, I.D. "Structure-Based Strategies for Drug Design and Discovery", <i>Science</i> 257:1078-1082 (1992).
	Kuwana, M. et al. "T and B Cell Collaboration is Essential for the Autoantibody Response to DNA Topoisomerase 1 in Systemic Sclerosis", <i>J. Immunol.</i> 155:2703-2714 (1995).
	Laman, J.D. et al. "The Role of GP39 (CD40 Ligand) in EAE and MS", <i>J. Neuroimmunology</i> 54:175 (1994).
	Larsen, C.P. et al. "CD40-gp39 Interactions Play A Critical Role During Allograft Rejection", <i>Transplantation</i> 61:4-9 (1996).
	Law, C-L. et al. "Analysis of Expression and Function of CD40 on Normal and Leukemic Human B Cell Precursors", <i>Leukemia</i> 4(11):732-738 (1990).
	Lederman, S. et al. "The Understanding of Contact-Dependent T-Cell Helper Function in Molecular, Cellular and Physiological Detail", <i>Res. Immunol.</i> 145:215-222 (1994).
	Mohan, C. et al. "Interaction Between CD40 and Its Ligand gp39 in the Development of Murine Lupus Nephritis", <i>J. Immunol.</i> 154:1470-1480 (1995).
	Merck Manual of Diagnosis And Therapy, 16th Ed. "Idiopathic Infiltrative Diseases Of The Lungs", Merck Research Laboratories, Rahway, NJ 718-720 (1992).
	O'Grady, J.T. et al. "CD40 Expression in Hodgkin's Disease", <i>Am. J. Of Pathology</i> 144:(1):2126 (1994).
	Paulie, S. et al. "A p50 Surface Antigen Restricted to Human Urinary Bladder Carcinomas and B Lymphocytes", <i>Cancer Immunol. Immunother.</i> 20:23-28 (1985).
	Potocnik, A.J. et al. "Expression of Activation Antigens on T Cells in Rheumatoid Arthritis Patients", <i>Scand. J. Immunol.</i> 31:213-224 (1990).
	Stüber, E. et al. "Blocking The CD-40L-CD-40 Interaction In Vivo Specifically Prevents the Priming of T Helper 1 Cells Through The Inhibition of Interleukin 12 Secretion", <i>J. Exp. Med.</i> 183: 693-698 (1996).
	Uckun, F.M. et al. "Temporal Association of CD40 Antigen Expression With Discrete Stages of Human B-Cell Ontogeny and the Efficacy of Anti-CD40 Immunotoxins Against Clonogenic B-Lineage Acute Lymphoblastic Leukemia As Well As B-Lineage Non-Hodgkin's Lymphoma Cells", <i>Blood</i> 76(12):2449-2456 (1990).
	Urashima, M. et al. "CD40 Ligand Triggered Interleukin-6 Secretion In Multiple Myeloma", <i>Blood</i> 85:1903-1912 (1995).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. CO14CIP DIV2	SERIAL NO. Not Yet Assigned
	APPLICANT Michael J. Yellin et al.	
	FILING DATE Concurrently Herewith	GROUP Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.